AAAAAA

   
Results: 1-23 |
Results: 23
SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA
Authors: CORTES J TALPAZ M OBRIEN S RIOS MB MAJLIS A KEATING M FREIREICH EJ KANTARJIAN H
Citation: J. Cortes et al., SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 16(10), 1998, pp. 3279-3285
TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY
Authors: BERAN M JEHA S OBRIEN S ESTEY E VITEK L ZURLO MG RIOS MB KEATING M KANTARJIAN H
Citation: M. Beran et al., TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY, Clinical cancer research, 3(12), 1997, pp. 2377-2384
THE HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: KOLLER CA KANTARJIAN HM THOMAS D OBRIEN S RIOS MB KORNBLAU S MURPHY S KEATING M
Citation: Ca. Koller et al., THE HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA, Leukemia, 11(12), 1997, pp. 2039-2044
RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA
Authors: KANTARJIAN HM OBRIEN SM KEATING M BERAN M ESTEY E GIRALT S KORNBLAU S RIOS MB DEVOS D TALPAZ M
Citation: Hm. Kantarjian et al., RESULTS OF DECITABINE THERAPY IN THE ACCELERATED AND BLASTIC PHASES OF CHRONIC MYELOGENOUS LEUKEMIA, Leukemia, 11(10), 1997, pp. 1617-1620
DECITABINE STUDIES IN CHRONIC AND ACUTE MYELOGENOUS LEUKEMIA
Authors: KANTARJIAN HM OBRIEN SM ESTEY E GIRALT S BERAN M RIOS MB KEATING M DEVOS D TALPAZ M
Citation: Hm. Kantarjian et al., DECITABINE STUDIES IN CHRONIC AND ACUTE MYELOGENOUS LEUKEMIA, Leukemia, 11, 1997, pp. 35-36
A PHASE I II TRIAL OF INCREASING DOSES OF MITOXANTRONE WITH FLUDARABINE AND CYTARABINE (FAM REGIMEN) IN RELAPSED ACUTE-LEUKEMIA AND CHRONICMYELOGENEOUS LEUKEMIA IN BLASTIC PHASE (CML-BP)/
Authors: KOLLER CA KANTARJIAN H FELDMAN E ESTEY E OBRIEN S RIOS MB KEATING M
Citation: Ca. Koller et al., A PHASE I II TRIAL OF INCREASING DOSES OF MITOXANTRONE WITH FLUDARABINE AND CYTARABINE (FAM REGIMEN) IN RELAPSED ACUTE-LEUKEMIA AND CHRONICMYELOGENEOUS LEUKEMIA IN BLASTIC PHASE (CML-BP)/, Blood, 90(10), 1997, pp. 3834-3834
DECITABINE, A HYPOMETHYLATING AGENT SHOWS ENCOURAGING RESULTS IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) IN TRANSFORMATION
Authors: KANTARJIAN H OBRIEN S KEATING M RIOS MB TALPAZ M
Citation: H. Kantarjian et al., DECITABINE, A HYPOMETHYLATING AGENT SHOWS ENCOURAGING RESULTS IN THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) IN TRANSFORMATION, Blood, 90(10), 1997, pp. 352-352
HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: KOLLER CA KANTARJIAN HM THOMAS D OBRIEN S RIOS MB KORNBLAU S MURPHY S KEATING M
Citation: Ca. Koller et al., HYPER-CVAD REGIMEN IMPROVES OUTCOME IN RELAPSED ACUTE LYMPHOBLASTIC-LEUKEMIA, Blood, 90(10), 1997, pp. 1482-1482
EVALUATION OF CL-973, A PLATINUM ANALOG, IN REFRACTORY OR RELAPSED ACUTE-LEUKEMIA
Authors: KANTARJIAN HM BERAN M OBRIEN S ROBERTSON L SIDDIK Z YOSHIDA M YANG LY RIOS MB KEATING MJ MEYER M KOWAL C ESTEY EH
Citation: Hm. Kantarjian et al., EVALUATION OF CL-973, A PLATINUM ANALOG, IN REFRACTORY OR RELAPSED ACUTE-LEUKEMIA, Leukemia, 10(3), 1996, pp. 396-401
SIGNIFICANCE OF CYTOGENETIC CLONAL EVOLUTION IN CHRONIC MYELOGENOUS LEUKEMIA
Authors: MAJLIS A SMITH TL TALPAZ M OBRIEN S RIOS MB KANTARJIAN HM
Citation: A. Majlis et al., SIGNIFICANCE OF CYTOGENETIC CLONAL EVOLUTION IN CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 14(1), 1996, pp. 196-203
TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SCID MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA (AML), INDUCES REMISSIONS IN A PHASE STUDY
Authors: BERAN M JEHA S OBRIEN S ESTEY E VITEK L ZURLO M RIOS MB KEATING M KANTARJIAN H
Citation: M. Beran et al., TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SCID MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA (AML), INDUCES REMISSIONS IN A PHASE STUDY, Blood, 88(10), 1996, pp. 868-868
FISH IDENTIFIES EITHER LOW-FREQUENCY OF PH-22, IN PH CHROMOSOME-NEGATIVE, BCR REARRANGED CHRONIC MYELOGENOUS LEUKEMIA( CELLS, OR INSERTION OF A PORTION OF THE ABL GENE REGION INTO CHROMOSOME)
Authors: SEONG D KANTARJIAN H ALBITAR M ARLINGHAUS R SWANTKTOWSKI J XU JP RIOS MB KOH YH GUO JO OBRIEN S FREIREICH EJ SICILIANO MJ
Citation: D. Seong et al., FISH IDENTIFIES EITHER LOW-FREQUENCY OF PH-22, IN PH CHROMOSOME-NEGATIVE, BCR REARRANGED CHRONIC MYELOGENOUS LEUKEMIA( CELLS, OR INSERTION OF A PORTION OF THE ABL GENE REGION INTO CHROMOSOME), Blood, 88(10), 1996, pp. 1470-1470
HOMMOHARRINGTONINE (HHT) AND LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) COMBINATION THERAPY HAS SIGNIFICANT ACTIVITY IN PATIENTS (PTS) WITH LATE-PHASE PHILADELPHIA-CHROMOSOME (PH) - POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML)
Authors: KANTARJIAN H OBRIEN S KEATING M BERAN M KOLLER C ESTEY E KORNBLAU S RIOS MB TALPAZ M
Citation: H. Kantarjian et al., HOMMOHARRINGTONINE (HHT) AND LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) COMBINATION THERAPY HAS SIGNIFICANT ACTIVITY IN PATIENTS (PTS) WITH LATE-PHASE PHILADELPHIA-CHROMOSOME (PH) - POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 88(10), 1996, pp. 2299-2299
COLLECTION OF PERIPHERAL-BLOOD DIPLOID-CELLS FROM CHRONIC MYELOGENOUSLEUKEMIA PATIENTS EARLY IN THE RECOVERY PHASE FROM MYELOSUPPRESSION INDUCED BY INTENSIVE-DOSE CHEMOTHERAPY
Authors: KANTARJIAN HM TALPAZ M HESTER J FELDMAN E KORBLING M LIANG J RIOS MB SMITH TL CALVERT L DEISSEROTH AB
Citation: Hm. Kantarjian et al., COLLECTION OF PERIPHERAL-BLOOD DIPLOID-CELLS FROM CHRONIC MYELOGENOUSLEUKEMIA PATIENTS EARLY IN THE RECOVERY PHASE FROM MYELOSUPPRESSION INDUCED BY INTENSIVE-DOSE CHEMOTHERAPY, Journal of clinical oncology, 13(3), 1995, pp. 553-559
THE BREAKPOINT CLUSTER REGION SITE IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA - CLINICAL, LABORATORY, AND PROGNOSTIC CORRELATIONS
Authors: VERSCHRAEGEN CF KANTARJIAN HM HIRSCHGINSBERG C LEE MS OBRIEN S RIOS MB STASS SA KEATING M TALPAZ M
Citation: Cf. Verschraegen et al., THE BREAKPOINT CLUSTER REGION SITE IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA - CLINICAL, LABORATORY, AND PROGNOSTIC CORRELATIONS, Cancer, 76(6), 1995, pp. 992-997
PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA WITH REARRANGEMENT OF THE BREAKPOINT CLUSTER REGION - LONG-TERM FOLLOW-UP RESULTS
Authors: CORTES JE TALPAZ M BERAN M OBRIEN SM RIOS MB STASS S KANTARJIAN HM
Citation: Je. Cortes et al., PHILADELPHIA CHROMOSOME-NEGATIVE CHRONIC MYELOGENOUS LEUKEMIA WITH REARRANGEMENT OF THE BREAKPOINT CLUSTER REGION - LONG-TERM FOLLOW-UP RESULTS, Cancer, 75(2), 1995, pp. 464-470
INTERFERON-ALPHA (IFN-A) AND LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) THERAPY IN PHILADELPHIA-CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML)
Authors: KANTARJIAN H OBRIEN S BERAN M KOLLER C ANDREEFF M RIOS MB KEATING M FREIREICH E TALPAZ M
Citation: H. Kantarjian et al., INTERFERON-ALPHA (IFN-A) AND LOW-DOSE CYTOSINE-ARABINOSIDE (ARA-C) THERAPY IN PHILADELPHIA-CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML), Blood, 86(10), 1995, pp. 2105-2105
QUANTIFICATION OF THE BREAKPOINT CLUSTER REGION REARRANGEMENT FOR CLINICAL MONITORING IN PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOID-LEUKEMIA
Authors: VERSCHRAEGEN CF TALPAZ M HIRSCHGINSBERG CF PHERWANI R RIOS MB STASS SA KANTARJIAN HM
Citation: Cf. Verschraegen et al., QUANTIFICATION OF THE BREAKPOINT CLUSTER REGION REARRANGEMENT FOR CLINICAL MONITORING IN PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOID-LEUKEMIA, Blood, 85(10), 1995, pp. 2705-2710
HIGH-DOSES OF CYCLOPHOSPHAMIDE, ETOPOSIDE AND TOTAL-BODY IRRADIATION FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION IN THE MANAGEMENT OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
Authors: TALPAZ M ANDERSSON B KHOURI I GIRALT S RIOS MB KANTARJIAN HM CHAMPLIN R HESTER J DEISSEROTH AB
Citation: M. Talpaz et al., HIGH-DOSES OF CYCLOPHOSPHAMIDE, ETOPOSIDE AND TOTAL-BODY IRRADIATION FOLLOWED BY AUTOLOGOUS STEM-CELL TRANSPLANTATION IN THE MANAGEMENT OF PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA, Bone marrow transplantation, 14(1), 1994, pp. 57-61
HIGH-DOSE CHEMOTHERAPY AND UNPURGED AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) - THE ANDERSON,M.D. EXPERIENCE
Authors: KHOURI IF KANTARJIAN HM TALPAZ M RIOS MB GIRALT S HESTER JP CHAMPLIN RE DEISSEROTH AB
Citation: If. Khouri et al., HIGH-DOSE CHEMOTHERAPY AND UNPURGED AUTOLOGOUS STEM-CELL TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA (CML) - THE ANDERSON,M.D. EXPERIENCE, Blood, 84(10), 1994, pp. 10000537-10000537
FLUDARABINE AND ARABINOSYLCYTOSINE THERAPY OF REFRACTORY AND RELAPSEDACUTE MYELOGENOUS LEUKEMIA
Authors: ESTEY E PLUNKETT W GANDHI V RIOS MB KANTARJIAN H KEATING MJ
Citation: E. Estey et al., FLUDARABINE AND ARABINOSYLCYTOSINE THERAPY OF REFRACTORY AND RELAPSEDACUTE MYELOGENOUS LEUKEMIA, Leukemia & lymphoma, 9(4-5), 1993, pp. 343-350
EFFECT OF PRIOR INTERFERON-ALFA THERAPY ON THE OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA
Authors: GIRALT SA KANTARJIAN HM TALPAZ M RIOS MB DELGIGLIO A ANDERSSON BS PRZEPIORKA D DEISSEROTH AB CHAMPLIN RE
Citation: Sa. Giralt et al., EFFECT OF PRIOR INTERFERON-ALFA THERAPY ON THE OUTCOME OF ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA, Journal of clinical oncology, 11(6), 1993, pp. 1055-1061
FLUDARABINE AND CYTOSINE-ARABINOSIDE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE LYMPHOCYTIC-LEUKEMIA
Authors: SUKI S KANTARJIAN H GANDHI V ESTEY E OBRIEN S BERAN M RIOS MB PLUNKETT W KEATING M
Citation: S. Suki et al., FLUDARABINE AND CYTOSINE-ARABINOSIDE IN THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE LYMPHOCYTIC-LEUKEMIA, Cancer, 72(7), 1993, pp. 2155-2160
Risultati: 1-23 |